JAK1 and ovarian cancer: To validate this concept, we demonstrated that inhibition of STAT3 activation in vitro was able to reverse HCT116-induced C2C12 myotube atrophy, in line with our previous observations that inhibition of STAT3 by use of the pharmacologic JAK1/2 inhibitor INCB018424 also rescues myotube atrophy induced by ES-2 ovarian cancer-derived conditioned media (Pin et al., 2018).